Actively Recruiting
The CoAGulation Biomarkers and Atrial Fibrillation (COAG-AF) Pilot Study
Led by Tulane University · Updated on 2026-03-05
20
Participants Needed
3
Research Sites
323 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of the Correlation Of CoAGulation-Atrial Fibrillation (COAG-AF) study is to prove that an increase in pro-thrombotic biomarkers in AF is associated with an increase in AF burden. Secondary objectives of the study are the following: * To investigate the impact of catheter ablation on serum pro-thrombotic biomarkers in patients with AF. * To correlate coagulation biomarkers with imaging features such as, the degree of fibrosis found on Late Gadolinium Enhancement Magnetic Resonance Imaging (LGE-MRI) scans, which is a part of standard of care. * To determine baseline values of coagulation and pro-thrombotic biomarkers in the AF population and compare those baseline values with the general population values. * To compare central and peripheral thrombotic biomarkers in patients with atrial fibrillation.
CONDITIONS
Official Title
The CoAGulation Biomarkers and Atrial Fibrillation (COAG-AF) Pilot Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female patients older than 18 years
- Diagnosed with persistent or paroxysmal atrial fibrillation
- Undergoing catheter ablation at Tulane University Medical Center
- Cardiac MRI prescribed as part of standard care by their physician
You will not qualify if you...
- Patients with coagulation disorders such as von Willebrand disease, hemophilia, or Immune Thrombocytopenic Purpura
- Pregnant or breastfeeding, or planning pregnancy during the study
- Not surgically sterile and of childbearing potential unwilling to use two effective birth control methods
- Unable or unwilling to continue using two effective birth control methods during the trial
- Mental or physical conditions that prevent active participation
- Contraindications to gadolinium/MRI, including allergy or implants like pacemakers or ICDs
- Known terminal illness with prognosis less than 12 months
- Planned cardiovascular intervention during the study
- Severe acute or chronic kidney disease with low glomerular filtration rate (<30 mL/min/1.73 m2)
- Cannot read, speak, or understand English
- Cognitive impairments preventing informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
East Jefferson General Hospital
New Orleans, Louisiana, United States, 70006
Actively Recruiting
2
University Medical Center
New Orleans, Louisiana, United States, 70112
Actively Recruiting
3
Tulane Doctors - Speciality Care - Napoleon
New Orleans, Louisiana, United States, 70115
Actively Recruiting
Research Team
M
Mayana Bsoul, MD
CONTACT
K
Kunal Sameer, MD, MHA
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here